OBJECTIVES: Treatment for metastatic castrate-resistant prostate cancer (mCRPC) has evolved rapidly with the introductions of abiraterone, denosumab and cabazitaxel in 2011 and enzalutamide in 2013 and the subsequent funding of these new agents.  Our objective is to describe the treatments used after a diagnosis of mCRPC in Canada.  METHODS: The study used ONCO-CAPPS, a proprietary database of patient chart abstractions collected through regular survey of physician panels.  The data includes the stage of the disease along with a summary of treatment from diagnosis.  Data from 2011 and 2013 were used to identify patients with mCRPC and to describe the treatments used.  Hormone therapies are grouped as follows: H1 is Luteinizing-Hormone-Releasing Hormone analogs, H2 is anti-androgens while H3 is ketoconazole, prednisone, abiraterone or enzalutamide. Chemotherapy includes docetaxel and cabazitaxel.  Pamidronate, zoledronic acid or denosumab are bone-targeted agents (BTA). RESULTS: All patients with mCRPC are treated with a combination of hormones, with or without docetaxel and/or a BTA.  In 2011, the proportions of mCRPC patients who were treated with regimens containing H1, H2 and H3 were 93%, 43% and 12% respectively. In 2013, the proportions of mCRPC patients who were treated with regimens containing H1, H2 and H3 were 86%, 37% and 35% respectively.  Between 2011 and 2013, the proportions of patients treated with a regimen containing docetaxel increased from 14% to 22% and the proportions of patients receiving an injectable BTA increased from 42% to 66%. In this period, the average age of patients treated with docetaxel was 69 years while that of patients treated with an H3 was 73 years. CONCLUSIONS: With the introduction of the new agents, a greater proportion of mCRPC patients are treated with a regimen containing docetaxel, an H3 and a BTA.  Docetaxel-treated patients are younger than those receiving an H3.